New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
May 15, 2014
09:26 EDTPCYC, INCYNomura is a buyer of Incyte and Pharmacyclics into ASCO meetings
Nomura is a buyer of Incyte (INCY) and Pharmacyclics (PCYC) following the ASCO abstract releases. The firm expects 50mg dose data on June 2 to meet investor expectations and for shares to recover. For Pharmacyclics, the analyst expects investor focus to be on negativity rates of Phase I/II trial of competitor ABT-199 + Rituxan and Imbruvica RESONATE Phase III data on June 3.
News For INCY;PCYC From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | 3 | all recent news | >>
February 27, 2015
14:47 EDTPCYCPharmacyclics says preclinical work needed before Phase II BTK inhibitor program
Pharmacyclics announced that longer-term toxicology studies for its newly developed Bruton's tyrosine kinase, or BTK, inhibitor for rheumatoid arthritis, or RA, have been completed. The results of these preclinical evaluations have been communicated to the FDA. The feedback received from the Agency is supportive of the completion of the ongoing first-in-human study. Additional preclinical work is required to begin a Phase II clinical development program in autoimmune diseases with this investigational compound. "The company does not anticipate initiating a Phase II study until additional preclinical work is successfully completed. Further updates on the progress of these efforts will be provided when appropriate," Pharmacyclics said.
14:34 EDTPCYCPharmacyclics says Imbruvica combination enhances anti-tumor activity
Subscribe for More Information
09:58 EDTPCYCOn The Fly: Analyst Downgrade Summary
Today's noteworthy downgrades include: 500.com (WBAI) downgraded to Hold from Buy at Deutsche Bank... Akorn (AKRX) downgraded to Hold after share rally at Needham... Allscripts (MDRX) downgraded to Market Perform from Outperform at Leerink... Bank of America (BAC) downgraded to Neutral from Buy at UBS... Bill Barrett (BBG) downgraded to Hold from Buy at KLR Group... CA Technologies (CA) downgraded to Underperform from Neutral at Credit Suisse... CBOE Holdings (CBOE) downgraded at BofA/Merrill... CONE Midstream (CNNX) downgraded to Sector Perform from Outperform at RBC Capital... Calamos (CLMS) downgraded to Underperform from Neutral at Credit Suisse... Crane (CR) downgraded to Market Perform from Outperform at FBR Capital... Dick's Sporting (DKS) downgraded to Equal Weight from Overweight at Barclays... EnerNOC (ENOC) downgraded to Buy from Strong Buy at Needham... Hercules Offshore (HERO) downgraded to Sell from Buy at Deutsche Bank... Insulet (PODD) downgraded at Oppenheimer... Intelsat (I) downgraded to Underperform from Neutral at Credit Suisse... Laredo Petroleum (LPI) downgraded to Market Perform from Outperform at Northland... Mavenir Systems (MVNR) downgraded to Equal Weight from Overweight at Morgan Stanley... Memorial Production (MEMP) downgraded to Underperform from Perform at Oppenheimer... Mobileye (MBLY) downgraded to Neutral from Buy at Dougherty... NTELOS (NTLS) downgraded to Market Perform from Outperform at Wells Fargo... Ocwen (OCN) downgraded to Sell from Neutral at Compass Point... Pegasystems (PEGA) downgraded to Neutral from Buy at Merriman... Performant Financial (PFMT) downgraded to Neutral from Buy at Compass Point... Pharmacyclics (PCYC) downgraded to Neutral from Buy at Goldman... Potbelly (PBPB) downgraded to Underweight from Overweight at Piper Jaffray... SYNNEX (SNX) downgraded to Hold from Buy at Stifel... Safe Bulkers (SB) downgraded at Credit Suisse... Sarepta (SRPT) downgraded to Market Perform from Outperform at Cowen... Seadrill Partners (SDLP) downgraded to Sector Perform from Outperform at RBC Capital... Spirit Realty (SRC) downgraded at RBC Capital... Transocean (RIG) downgraded to Sector Perform from Outperform at Iberia... UIL Holdings (UIL) downgraded to Neutral from Outperform at RW Baird... WCI Communities (WCIC) downgraded to Neutral from Buy at Citigroup... Walter Investment (WAC) downgraded to Neutral from Outperform at Credit Suisse.
08:15 EDTPCYCJohnson & Johnson would benefit from Pharmacyclics deal, says Wells Fargo
After Bloomberg and The Financial Times reported that Johnson & Johnson (JNJ) and Novartis (NVS) are interested in buying Pharmacyclics (PCYC), Wells Fargo thinks the deal would cause a slight acceleration of Johnson & Johnson's revenue growth. The firm believes that the deal could be slightly dilutive to Johnson & Johnson's EPS in the first full year and 1%-4% accretive thereafter. Wells keeps an Outperform rating on Johnson & Johnson.
07:59 EDTPCYCPharmacyclics risk/reward unappealing, says Bernstein
Subscribe for More Information
06:56 EDTPCYCPharmacyclics downgraded to Neutral from Outperform at Credit Suisse
Subscribe for More Information
February 26, 2015
18:06 EDTPCYCPharmacyclics downgraded to Neutral from Buy at Goldman
Subscribe for More Information
10:00 EDTPCYCOn The Fly: Analyst Downgrade SummaryStarz
Subscribe for More Information
09:03 EDTPCYCPharmacyclics price target raised to $240 from $200 at RW Baird
Subscribe for More Information
07:37 EDTINCYIncyte to sponsor U.S. polycythemia vera study
Incyte announced that it is sponsoring the first major observational study of patients living with polycythemia vera in the U.S. PV is a rare and progressive blood cancer that can lead to debilitating symptoms, serious cardiovascular complications, and death.The REVEAL study will seek to describe the real-world clinical burden of PV and how healthcare services are utilized in the management of this disease. Incyte is partnering with approximately 200 community and academic medical centers to conduct the study in the U.S. REVEAL, which recently began enrolling patients, is expected to include 2,000 patients under the supervision of a physician for the active management of PV for a period of three years.
06:52 EDTPCYCPharmacyclics downgraded to Hold from Buy at WallachBeth
Subscribe for More Information
February 25, 2015
14:47 EDTPCYCPharmacyclics could fetch as much as $19B in sale, FT says
Pharmacyclics (PCYC) is considering a sale that could fetch as much as $19B, reported Financial Times, citing people familiar with the matter who said Johnson & Johnson (JNJ) is exploring a potential deal for the company. The Fly notes that Bloomberg had a similar report, but its report said Pharmacyclics could fetch $17B-$18B in a sale. Reference Link
14:10 EDTPCYCPharmacyclics downgraded to Hold on lack of upside at Deutsche Bank
Subscribe for More Information
14:02 EDTPCYCPharmacyclics downgraded to Hold from Buy at Deutsche Bank
Subscribe for More Information
13:30 EDTPCYCPharmacyclics calls active on exploring options reports
Pharmacyclics March 220 and April 230 calls are active on total call volume of 4,200 contracts (3,100 puts) on exploring options including sale, Bloomberg reports. Active call volume suggests traders taking positions for upside price movement.
12:54 EDTPCYCPharmacyclics exploring options including sale, Bloomberg reports
According to sources, Pharmacyclics (PCYC), which develops cancer treatments, is currently exploring options, Bloomberg reports. One option may include a sale of the company, and the sources say Johnson & Johnson (JNJ) and Novartis (NVS) have expressed interest in the company. Pharmacyclics could fetch $17B-$18B in a sale, the sources add. Reference Link
12:53 EDTPCYCPharmacyclics weighing sale to U.S. drugmaker, Bloomberg reports
Subscribe for More Information
12:50 EDTPCYCPharmacyclics jumps 19% after Bloomberg says weighing sale
Subscribe for More Information
February 23, 2015
07:30 EDTINCYIncyte price target raised to $89 from $75 at Oppenheimer
Oppenheimer increased its price target on Incyte after the company reported that sales of its flagship Jakafi drug had jumped 46% year-over-year in Q4. The firm continues to be upbeat on Jakafi's revenue outlook and the company's pipeline. It keeps an Outperform rating on the shares.
07:06 EDTINCYEli Lilly and Incyte announces positive results for baricitinib
Subscribe for More Information
1 | 2 | 3 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use